| Literature DB >> 35456796 |
Arezina N Kasti1, Maroulla D Nikolaki1, Kalliopi D Synodinou1, Konstantinos N Katsas1,2, Konstantinos Petsis1, Sophia Lambrinou1, Ioannis A Pyrousis1,3, Konstantinos Triantafyllou4.
Abstract
Stevia, a zero-calorie sugar substitute, is recognized as safe by the Food and Drug Administration (FDA) and the European Food Safety Authority (EFSA). In vitro and in vivo studies showed that stevia has antiglycemic action and antioxidant effects in adipose tissue and the vascular wall, reduces blood pressure levels and hepatic steatosis, stabilizes the atherosclerotic plaque, and ameliorates liver and kidney damage. The metabolism of steviol glycosides is dependent upon gut microbiota, which breaks down glycosides into steviol that can be absorbed by the host. In this review, we elucidated the effects of stevia's consumption on the host's gut microbiota. Due to the lack of randomized clinical trials in humans, we included in vitro using certain microbial strains and in vivo in laboratory animal studies. Results indicated that stevia consumption has a potential benefit on the microbiome's alpha diversity. Alterations in the colonic microenvironment may depend on the amount and frequency of stevia intake, as well as on the simultaneous consumption of other dietary components. The anti-inflammatory properties of stevioside were confirmed in vitro by decreasing TNF-α, IL-1β, IL-6 synthesis and inhibiting of NF-κB transcription factor, and in vivo by inhibiting NF-κB and MAPK in laboratory animals.Entities:
Keywords: Stevia rebaudiana; bacteria; fecal flora; gut microbiota; stevioside
Year: 2022 PMID: 35456796 PMCID: PMC9028423 DOI: 10.3390/microorganisms10040744
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Figure 1Flow chart. Identification and selection of the studies.
In vitro studies presenting the effects of stevia and steviol glycosides on bacterial growth.
| Reference | Strains | Intervention | Control | Beneficial or No Effect on Bacterial Populations Growth | Adverse Effects on Bacterial Populations Growth |
|---|---|---|---|---|---|
| Markus et al. 2020 | REB-A | LB | Possible interruption of Gram-negative bacterial communication | ||
| Li et al. 2014 | REB-A | Saline buffer | No effect | ||
| Wang et al. 2018 | REB-A | LB with agar | Reduced | ||
| Deniņa et al. 2014 | REB-A | Acetic acid and lactic acid | Inhibit | ||
| Boling et al. 2020 | REB-A | None | Reduced | Increased | |
| Gerasimidis et al. 2020 |
| Stevia | None | No effect | |
| Mahalak et al. 2020 | Human gut microbiota | Steviol glycosides + erythritol | None | Increased | |
| Kunová et al. 2014 | Stevioside and REB-A (purity ≥ 95% of steviol glycosides), medium containing REB-A | MRS broth | Increased |
* p-value p < 0.05.
In vivo studies presenting the effects of stevia and steviol glycosides on bacterial growth.
| Reference | Type of Study | Model/Samples | Intervention | Control | Beneficial or No Effect on Bacterial Populations Growth | Adverse Effects on Bacterial Populations Growth |
|---|---|---|---|---|---|---|
| Becker et al. 2020 | Preclinical RCT | Mice | HFS + stevia | Saccharin | Increased | |
| Li et al. 2014 | Preclinical RCT | Mice | Low dose REB-A | None | Increased | |
| Nettleton et al. 2019 | Preclinical RCT | Rats | REB-A and | Water | Increased | Reduced |
| Nettleton et al. 2020 | Preclinical | Obese rats during pregnancy and lactation and their | HFS + REB-A | Lean rats | Obese rats and offspring | Obese rats |
| Wang et al. 2022 | Preclinical | Obese rats during pregnancy and lactation and their offspring | HFS + stevia | Rats during pregnancy and | Increased | |
| de la Garza et al. 2022 | Preclinical | Rats during pregnancy and lactation and their male offspring | In prenatal period: cafeteria diet. | Control diet | Maternal and male offspring group | Maternal and male offspring group |
| Mahalak et al. 2020 | Preclinical | Monkey | Steviol glycosides | - | No effect | |
| Yu et al. 2020 | Preclinical | Pregnant sows | Corn–soybean-meal diets | Control diet | Increased |
REB-A: Rebaudioside A; E. coli: Escherichia coli; LB: Lysogeny broth; MRS broth: de Man, Rogosa and Sharpe broth; HFS: high fat/high sucrose diet; E. faecalis: Enterococcus faecalis; S. aureus: Staphylococcus aureus; P. aeruginosa: Pseudomonas aeruginosa; B. thetaiotaomicron: Bacteroides thetaiotaomicron; L. rhamnosus: Lactobacillus rhamnosus; B. bifidum: Bifidobacterium bifidum; C. leptum: Clostridium leptum; A. muciniphila: Akkermansia muciniphila; S. typhimurium: Salmonella typhimurium.
The effects of stevia and steviol glycosides on microbial diversity.
| Reference | Target Group | Evaluate | Alpha Diversity | Beta Diversity |
|---|---|---|---|---|
| Li et al. 2014 | Mice | a-diversity measures: Richness, H’A and SE |
DGGE using V3 universal primers or using DGGE using Richness: 11.2 ± 0.84 (SG) vs. 8.9 ± 0.84 (CG) H’AMAX: 2.41 ± 0.08 (SG) vs. 2.28 ± 0.08 (CG) | - |
| Nettleton et al. 2019 | Mice |
a-diversity measures: Chao, H’A and Simpson b-diversity measures: NMDS | NS difference in alpha diversity measures between CG and SG | NS difference in beta diversity measures between CG and SG |
| Nettleton et al. 2020 | Mice |
a-diversity measures: H’A, and Simpson b-diversity measures: weighted and unweighted UniFrac distances | Significantly higher a-diversity measures in SG compared to CG | NS difference in beta diversity measures between CG and SG |
| Wang et al. 2018 | Mice | a-diversity measure: H’A | NS difference in alpha diversity measures between CG and sucralose in normal chow or HFD-fed mice | - |
| Gerasimidis et al. 2020 | 13 healthy volunteers | a-diversity measures: OTUs, Chao, Rarefied richness, H’A, J’ | Addition of stevia significantly increased H’A, J’ and Rarefied richness (compared to CG) | - |
| de la Garza et al. 2022 | Mice (male) | a-diversity measure: H’A |
Significantly higher H’A in CG compared to SG during breastfeeding. NS difference in H’A during adulthood period (CG vs. SG). NS difference in H’A between breastfeeding and adulthood period in SG. | - |
| Mahalak et al. 2020 | In vitro |
a-diversity measures: Species Richness, H’A, and Fa b-diversity measures: weighted and unweighted UniFrac distances | NS difference in alpha diversity measures over time between CG, Erythritol group and SN Stevia group | No consistent pattern was observed between each group |
| 1 volunteer | Consumption of SN Stevia & Erythritol increased alpha diversity measures significantly over time ( | NS difference in beta diversity measures over time | ||
| Yu et al. 2020 | Sows | a-diversity measures: OTUs, Sobs, Chao1, Ace, H’A, Simpson, Coverage index | NS difference in alpha diversity measure between CG and experimental groups fed with stevia residue |
NS: No significant difference (p > 0.05); HFD: high-fat diet; CG: control group; SG: Stevia group; H’A: Shannon index OR Shannon’s diversity index OR Shannon–Wiener index (same); SE: Shannon evenness index; J’: Pielou’s evenness; OTUs: operational taxonomic units; Chao: Chao1 richness; Fa: Faith’s Phylogenetic Diversity Index; NMDS: Nonmetric multidimensional scaling on a Bray–Curtis dissimilarity matrix.
The effects of stevia glycosides on certain beneficial and harmful bacteria growth in in vitro and in vivo studies, without any dietary intervention.
| Ref | Beneficial Effect | Harmful Effect | ||
|---|---|---|---|---|
| Beneficial Strains Growth | Suppression of Pathogens | Suppression of Beneficial Strains | Pathogen Growth | |
| [ |
|
| ||
| [ |
| |||
| [ | ||||
| [ | ||||
| [ |
|
|
| |
| [ |
| |||
| [ | ||||
Figure 2The anti-inflammatory effect of stevia glycosides through inhibition of transcription factor NF-κB and mitogen-activated protein kinase (MAPK). Figure created using Servier Medical Art (www.servier.com; accessed on 28 January 2022) under a Creative Commons Attribution 3.0 Unported license.